Compugen (NASDAQ:CGEN) CEO Sells $16,000.00 in Stock

Compugen Ltd. (NASDAQ:CGEN) CEO Eran Ophir sold 5,000 shares of the company’s stock in a transaction dated Friday, April 24th. The stock was sold at an average price of $3.20, for a total transaction of $16,000.00. Following the completion of the sale, the chief executive officer directly owned 11,375 shares of the company’s stock, valued at approximately $36,400. This trade represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Eran Ophir also recently made the following trade(s):

• On Tuesday, April 14th, Eran Ophir sold 5,000 shares of Compugen stock. The stock was sold at an average price of $2.90, for a total transaction of $14,500.00.
• On Wednesday, April 1st, Eran Ophir sold 5,625 shares of Compugen stock. The stock was sold at an average price of $2.21, for a total transaction of $12,431.25.

Compugen Price Performance

NASDAQ:CGEN opened at $2.60 on Thursday. Compugen Ltd. has a 1-year low of $1.23 and a 1-year high of $3.23. The company has a 50-day moving average of $2.30 and a 200 day moving average of $1.92. The firm has a market cap of $245.84 million, a PE ratio of 7.03 and a beta of 2.77.

Compugen (NASDAQ:CGEN) last released its quarterly earnings data on Monday, March 2nd. The biotechnology company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.05 by $0.55. Compugen had a net margin of 48.57% and a return on equity of 55.68%. The company had revenue of $67.33 million during the quarter, compared to analyst estimates of $14.30 million. Sell-side analysts anticipate that Compugen Ltd. will post -0.26 EPS for the current fiscal year.

Institutional Trading of Compugen

Several hedge funds have recently modified their holdings of CGEN. Bank Hapoalim BM acquired a new position in shares of Compugen during the fourth quarter valued at about $37,000. Security National Bank of Sioux City Iowa IA acquired a new position in shares of Compugen during the fourth quarter valued at about $38,000. Franklin Resources Inc. acquired a new position in shares of Compugen during the second quarter valued at about $56,000. Osaic Holdings Inc. increased its holdings in shares of Compugen by 346.0% during the second quarter. Osaic Holdings Inc. now owns 43,885 shares of the biotechnology company’s stock valued at $78,000 after acquiring an additional 34,045 shares in the last quarter. Finally, WINTON GROUP Ltd acquired a new position in shares of Compugen during the fourth quarter valued at about $84,000. 12.22% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have commented on CGEN. HC Wainwright began coverage on shares of Compugen in a research report on Wednesday, January 7th. They set a “buy” rating and a $4.00 price target for the company. Wall Street Zen raised shares of Compugen from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. Lake Street Capital began coverage on shares of Compugen in a research report on Tuesday, April 7th. They set a “buy” rating and a $6.00 price target for the company. Truist Financial raised shares of Compugen to a “strong-buy” rating in a research report on Wednesday, March 25th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Compugen in a research report on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $5.00.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.